The prognostic value of phosphorylated Akt in breast cancer: A systematic review

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yang, Zu Yao ^a   Di, Meng Yang ^a   Yuan, Jin Qiu ^a   Shen, Wei Xi ^b   Zheng, Da Yong ^c   Chen, Jin Zhang ^c   Mao, Chen ^a   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b JINAN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B;

BREAST TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; HUMAN; META ANALYSIS; METABOLISM; PHOSPHORYLATION; PUBLISHING; REGRESSION ANALYSIS;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PUBLICATION BIAS; REGRESSION ANALYSIS;

EID: 84922601189     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07758     Document Type: Review

References (60)

1. International Agency for Research on Cancer. GLOBOCAN2012: estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx [Accessed July 25, 2014].
2. Patani, N.,Martin, L.A.&Dowsett, M. Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer 133, 1-13 (2013).
3. Nicholson, K.M. & Anderson, N. G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14, 381-395 (2002).
4. Altomare, D. A. & Testa, J. R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464 (2005).
5. Xue, G. & Hemmings, B. A. PKB/Akt-dependent regulation of cell motility. J Natl Cancer Inst 105, 393-404 (2013).
6. Al-Bazz, Y. O., Underwood, J. C., Brown, B. L. & Dobson, P. R. Prognostic significance of Akt, phospho-Akt and BAD expression in primary breast cancer. Eur J Cancer 45, 694-704 (2009).
7. Alkan, S. & Izban, K. F. Immunohistochemical localization of phosphorylated AKT in multiple myeloma. Blood 99, 2278-2279 (2002).
8. Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23, 1-9 (2008).
9. Nakanishi, K., Sakamoto, M., Yamasaki, S., Todo, S. & Hirohashi, S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103, 307-312 (2005).
10. Nam, S. Y. et al. Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis. APMIS 111, 1105-1113 (2003).
11. Yang, X. et al. Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma [article in Chinese]. Zhonghua Bing Li Xue Za Zhi 40, 799-804 (2011).
12. Yang, Y. et al. Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: A meta-analysis. Int J Cancer 135, 1417-1424 (2014).
13. Xia, W. et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10, 3815-3824 (2004).
14. Fabi, A. et al. Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Oncology 78, 141-149 (2010).
15. An, J. et al. Phosphorylated Akt and phosphorylated mTOR expression in breast invasive carcinomas: analysis of 530 cases. J Breast Cancer 13, 337-348 (2010).
16. Andre, F. et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol 19, 315-320 (2008).
17. Benesch, C. et al. The clinicopathological and prognostic relevance of pyruvate kinase M2 and pAkt expression in breast cancer. Anticancer Res 30, 1689-1694 (2010).
18. Capodanno, A. et al.Dysregulated PI3K/Akt/PTEN pathway is amarker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 40, 1408-1417 (2009).
19. Cicenas, J. et al. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 7, R394-401 (2005).
20. Gallardo, A. et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106, 1367-1373 (2012).
21. Gori, S. et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 20, 648-654 (2009).
22. Hartog, H. et al. Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat 129, 725-736 (2011).
23. Janssen, E. A. et al. Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged,55 years. Cell Oncol 29, 25-35 (2007).
24. Kirkegaard, T. et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207, 139-146 (2005).
25. Liu, C., Zhou, S., Ke, C. S., Li, N. P. & Wu, R. L. Activation and prognostic significance of AKT, NF-kappaB and STAT3 in breast cancer with lymph node metastasis and estrogen receptor expression [article in Chinese]. Ai Zheng 26, 929-936 (2007).
26. Perez-Tenorio, G. & Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86, 540-545 (2002).
27. Schmitz, K. J. et al. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol 59, 685-691 (2006).
28. Sun, L. M.,Wang, J. L., Song, M. & Song, J. Y. Activation and significance of Akt in signal regulatory pathway of human breast cancer [article in Chinese]. Zhonghua Zhong Liu Fang Zhi Za Zhi 13, 1232-1234 (2006).
29. Tokunaga, E. et al.Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118, 284-289 (2006).
30. Vestey, S. B. et al. Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. Eur J Cancer 41, 1017-1025 (2005).
31. Wang, A. Y., Lin, X. Y.,Wang, Q. X. & Li, J. M. Expression and significance of p-Akt, PTEN, and P-gp in patients with axillary node negative breast cancer [article in Chinese]. Shandong Yi Yao 51, 19-21 (2011).
32. Wang, L. X.&Chen, L. R. Expression and significance of Galectin-3 and p-AKT in invasive ductal carcinoma [article in Chinese]. Shi Yong Zhong Liu Za Zhi 25, 638-641 (2010).
33. Wang, X. L. et al. Expression of Akt and its clinical significance in breast carcinoma [article in Chinese]. Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi 25, 257-263 (2009).
34. Wang, X. L. et al. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERb and HER-2 expression. Tumori 97, 185-190 (2011).
35. Yamamoto, O., Gomyo, Y.,Hirooka, Y., Tsujitani, S. & Ikeguchi, M. Expression of phospho-Akt and PTEN proteins in human breast cancer in relation to tumor progression and patient survival. Yonago Acta medica 49, 19-27 (2006).
36. Yamashita, H. et al. Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer. Endocr Relat Cancer 15, 755-763 (2008).
37. Yonemori, K. et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 26, 344-349 (2009).
38. Yu, P., Zhou, L., Ke, W. & Li, K. Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol 136, 1283-1292 (2010).
39. Zhou, X. et al. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10, 6779-6788 (2004).
40. Aleskandarany, M. A. et al. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat 127, 407-416 (2011).
41. Nagai, M. A. et al. Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37, 41-49 (2010).
42. Spears, M. et al. Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression. J Pathol 227, 481-489 (2012).
43. Wang, C. et al. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation. Breast Cancer Res Treat 129, 373-386 (2011).
44. Wu, Y. et al.Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 10, R3 (2008).
45. Tang, J. L.& Liu, J. L. Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol 53, 477-484 (2000).
46. Cinti, C. et al. Activated Akt as an indicator of prognosis in gastric cancer. Virchows Arch 453, 449-455 (2008).
47. Chen, T. A. et al. Recombinant VP1, an Akt inhibitor, suppresses progression of hepatocellular carcinoma by inducing apoptosis and modulation of CCL2 production. PLoS One 6, e23317 (2011).
48. Pal, S. K., Reckamp, K., Yu, H. & Figlin, R. A. Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19, 1355-1366 (2010).
49. Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9, 1956-1967 (2010).
50. Sangai, T. et al. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18, 5816-5828 (2012).
51. Funda, Meric-Bernstam. Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT01277757 [Accessed July 25, 2014].
52. Lee, C. K. et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105, 595-605 (2013).
53. Parmar, M. K., Torri, V. & Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17, 2815-2834 (1998).
54. Pan, A., Sun, Q., Okereke, O. I., Rexrode, K. M. & Hu, F. B. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 306, 1241-1249 (2011).
55. Wells, G. A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp [Accessed July 25, 2014].
56. Thosani, N. et al. Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol 31, 623-630 (2013).
57. Deeks, J. J., Higgins, J. P. T. & Altman, D. G. eds. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins, J. P. T. & Green, S., eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org [Accessed July 25, 2014].
58. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. BMJ 327, 557-560 (2003).
59. Sterne, J. A. C., Egger, M. & Moher, F. eds. Chapter 10: Addressing reporting biases. In: Higgins, J. P. T. & Green, S. eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.www.cochrane-handbook.org [Accessed July 25, 2014].
60. Duval, S. & Tweedie, R. Trim and fill: a simple funnelplot based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455-463 (2000).